PMID: 30010301Jul 1, 2016Paper

Molecular therapies for Duchenne muscular dystrophy

No to hattatsu. Brain and development
Yasuhiro Takeshima

Abstract

Duchenne muscular dystrophy (DMD) is the most common inherited muscle disorder, which is characterized by progressive muscle wasting, ultimately resulting in the death of patients in their twenties or thirties. In DMD the dystrophin gene is mutated, which results in a deficiency of the muscle dystrophin. Although expression of dystrophin is a fundamental treatment for DMD, no effective treatment for DMD is available until now. Promising molecular therapies which are mutation-specific have been developed. Antisense oligonucleotide-mediated exon skipping that convert out-of-frame mRNA into in-frame mRNA, thereby enabling semifunctional dystrophin production, is recognized as the most promising treatment for DMD. We demonstrated that the intravenous administration of the antisense oligonucleotide against the splicing enhancer sequence induced exon skipping and produced the dystrophin protein in DMD case for the first time. After extensive studies, antisense oligonucleotides comprising different monomers have undergone clinical trials and provided favorable results, enabling improvements in ambulation of DMD patients Induction of the read-through of nonsense mutations is expected to produce dystrophin in DMD patients with nonsense ...Continue Reading

Related Concepts

Related Feeds

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.

Related Papers

Rinsho byori. The Japanese journal of clinical pathology
Yasuhiro Takeshima
Rinshō shinkeigaku = Clinical neurology
Yasuhiro Takeshima
Brain and nerve = Shinkei kenkyū no shinpo
Masafumi Matsuo, Yasuhiro Takeshima
No to hattatsu. Brain and development
Masafumi Matsuo
© 2022 Meta ULC. All rights reserved